Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-02-06
1997-12-09
Lilling, Herbert J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 54, 536 21, A61K 31725
Patent
active
056961006
ABSTRACT:
Methods of making and using, as prophylactics or therapeutics for preventing or treating certain diseases including cancer, O-desulfated heparin compositions, preferably 2-O, 3-O desulfated heparin compositions, wherein the methods permit regulating the degree of 2-O, 3-O desulfation to produce compositions that are variably desulfated upto about and 75% desulfated at the 2-O and 3-O positions, respectively.
REFERENCES:
patent: 4613665 (1986-09-01), Larm
patent: 4774231 (1988-09-01), Petitou et al.
patent: 4954637 (1990-09-01), Nitecki et al.
patent: 4990502 (1991-02-01), Lormeau et al.
patent: 5010063 (1991-04-01), Piani et al.
patent: 5104860 (1992-04-01), Piani et al.
patent: 5236910 (1993-08-01), Egidio et al.
patent: 5280016 (1994-01-01), Conrad
Article by Guo, et al., entitled "The Disaccharide Composition of Heparins and Heparan Sulfates" published by Academic Press, Inc. Analytical Biochemistry, 176:96-104 (1989).
Jaseja, et al., "Novel Regio-and Stereoselective Modifications of Heparin in Alkaline Solution. Nuclear Magnetic Resonance Spectroscopic Evidence" published by Can. J. Chem. 67:1449-1456 (1989).
Rej, et al., "Base-catalyzed Conversion of the a-L-iduronic acid 2-sulfate Unit of Heparin into a Unit of a-L-galacturonic Acid, and Related Reactions" published by Elsevier Science Publishers B.V., (1989).
Gershenson et al., "Tyrosine Transaminase Induction by Dexamethasone in a New Rat Liver Cell Line," Science, 170:859-861 (1970).
Purkerson et al., "N-Desulfated/Acetylated Heparin Ameliorates the Progression of Renal Disease in Rats with Subtotal Renal Ablation," J. Clin. Invest., 81:69-74 (1988).
Sache et al., "Partially N-Desulfated Heparin as a Non-anticoagulant Heparin: Some Physico-Chemical and Biological Properties," Thrombosis Res. 55:247-258 (1989).
Bienkowski et al., "Structural Characterization of the Oligosaccharids Formed by Depolymerization of Heparin with nitrous Acid," J. Biol. Chem., 260(1):356-363 (1985).
Folkman et al., "Angiogenesis Inhibition and Tumor Regression Caused by Heparin or a Heparin Fragment in the Presence of Cortisone," Science, 221:719-725 (1983).
Kohler et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," 256:495-297 (1975).
Liu et al., Adverse effects of alkali and acid on the anticoagulant potency of heparin, evaluated with methl 2-deoxy-2-sulfamino-.alpha.-D-glucopyranoside 3-sulfate as a model compound, Carbohyd. Res., 228:29-36 (1992).
Kosakai et al., "Ester Sulfates in Sulfated Oligosaccharides from the Deamination Prodcts of Procine Heparin and Whale Heparin," Chemistry and Biology of Heparin, 97-104 (1981).
Liu, et al., "Adverse Effects of Alkali and Acid on the Anticoagulant Potency of Heparin, Evaluated with methyl 2-deoxy-2-sulfamino-.alpha.-D-Glucopryanoside 3-Sulfate as Model Compound" Elsevier Science Publishers B.V., Amsterdam, Carbohydrate Research 228:29-36 (1992).
Fraidenraich et al., "Selective O-desulphation of Heparin in Triethylamine," Elsevier Science Publishers, Ltd., Carbohydrate Polymers, pp. 111-114 (1991).
Mitchell et al., "Inhibitors of Angiogenesis" Academic Press, Inc., pp. 139-148 (1992).
Hirsh et al., "Low Molecular Weight Heparin" The Journal of the American Society of Hematology, Blood, 79, No. 1:1-17 (1992).
Castellot, et al., "Heparin Potentiation of 3T3-Adipocyte Stimulated Angiogenesis: Mechanisms of Action on Endothelial Cells" Journal of Cellular Physiology, pp. 323-329 (1986).
Ishihara et al., "A Cell-Based Assay for Evaluating the Interaction of Heparin-like Molecules and Basic Fibroblast Growth Factor" Academic Press, Inc., 202:310-315 (1992).
Irimura et al., Biochemistry (1986) 25:5322-5328.
Bar-Ner et al., Blood 70(2) (1987) pp. 551-557.
Rone et al., Endocrinology 127(6) (1990) pp. 2821-2828.
Stokes et al., Lab Invest. 63(5) (1990) pp. 657-668.
Velluz et al., C.R. Acad. Sci. Paris (1959) 247:1521-1523.
Conrad, "Structure of Heparan Sulfate and Dermatan Sulfate," Annals of N.Y. Academy of Sci. 556:18-28 (1989).
Ishihara et al., "A Cell-Based Assay for Evaluating the Internation of Heparin-like Molecules and Basic Fibroblast Growth Factor," Analytical Biochem. 202:310-315 (1992).
Inoue et al., "Selective N-Desulfation of Heparin with Dimethyl Sulfoxide Containing Water or Methanol," Carbohydrate Res., 46:87-95 (1976).
Fransson et al., "Relationship Between Anticoagulant Activity of Heparin and Susceptibility to Periodate Oxidation," FEBS Letters, 97:(1):119-123 (1979).
Casu et al., "Retention of Antilepemic Activity by Periodate-oxidized Non-anti-coagulant Heparins," Arzneim-Forsch/Drug Res. 36:(I):4:637-642 (1986).
Fransson et al., "Periodate Oxidation and Alkaline Degradation of Heparin-Like Related Glycans," Carbohyd. Res. 80:131-145 (1980).
Shaklee et al., "Hydrazinolysis of heparin and other glycosaminoglycans," Biochem J., 217:187-197 (1984).
Guo et al., "Analysis of Oligosaccharides from Heparin by Reversed-Phase Ion-Pairing High-Performance Liquid Chromatography.sup.1," Analyt. Biochem. 168:54-62 (1988).
Folkman et al., "Angiostatic Steroids--Method of Discovery and Mechanism of Action," Ann. Surg., 206:374-383 (1987).
Fendly et al., "Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor," Hybridoma, 6:359-370 (1987).
Lloyd et al., "Preparation of .sup.35 Sulphamate Derivatives for Studies on Heparin Degrading Enzymes of Mammalian Origin," Biochem Pharma., 20:637-648 (1971).
Sobel et al., "Heparin Inhibition of von Willebrand Factor-dependent Platelet Function In Vitro and In Vivo," J. Clin. Invest. 87:1787-1793 (1992).
Rej et al., "Base-catalyzed conversion of the .alpha.-L-iduronic acid 2-sulfate unit of heparin into a unit of .alpha.-L-galacturonic acid, and related functions," Carbohyd. Res. 200:437-447 (1990).
Luben et al., "In Vitro Immunization as an Adjunct to the Production of Hybridomas Producing Antibodies against the Lymphokine Osteoclast Activating Factor," Molecular Immunol. 17:635-639 (1980).
Ayotte et al., "N.M.R. Spectroscopic Observations Related to the Function of Sulfate Groups in Heparin, Calcium Binding vs. Biological Activity," Carbohyd. Res. 145:267-277 (1986).
Charles et al., "Studies on Heparin. IV. Observations on the Chemistry of Heparin", Biochem. J. 30:1927-1933 (1936).
Reading "In Vitro Immunization for the Production of Antigen-Specific Lymphocyte Hybridomas," Methods in Enzymology, 121:18:27 (1986).
Boss et al., "An Improved In Vitro Immunization Procedure for the Production of Monoclonal Antibodies," Methods in Enzymology., 121:27-33 (1986).
Kelton, et al., "A Comparison of the Quantitative Bistocetin von Willebrand Factor Assay by Using Fresh and Fixed Platelets," Thromb. Res. 18:477-483 (1980).
Coyne, "Heparin--Past, Present and Future," Chemistry and Biology of Heparin, 9-17 (1981).
Holme Kevin R.
Liang Weisheng
Shaklee Patrick N.
Glycomed Incorporated
Lilling Herbert J.
LandOfFree
Method for controlling O-desulfation of heparin and compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for controlling O-desulfation of heparin and compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for controlling O-desulfation of heparin and compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1607775